Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results

BACKGROUND: The nonsteroidal mineralocorticoid receptor antagonist finerenone and the sodium–glucose cotransporter-2 inhibitor (SGLT-2i) canagliflozin reduce cardiorenal risk in albuminuric patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). At first glance, the results of Finereno...

Descripción completa

Detalles Bibliográficos
Autores principales: Agarwal, Rajiv, Anker, Stefan D, Filippatos, Gerasimos, Pitt, Bertram, Rossing, Peter, Ruilope, Luis M, Boletis, John, Toto, Robert, Umpierrez, Guillermo E, Wanner, Christoph, Wada, Takashi, Scott, Charlie, Joseph, Amer, Ogbaa, Ike, Roberts, Luke, Scheerer, Markus F, Bakris, George L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217637/
https://www.ncbi.nlm.nih.gov/pubmed/34850173
http://dx.doi.org/10.1093/ndt/gfab336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217637/
https://www.ncbi.nlm.nih.gov/pubmed/34850173
http://dx.doi.org/10.1093/ndt/gfab336

Ejemplares similares